Avidity Biosciences, Inc. (RNAM)

Avidity Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	18.76	10.9	9.56	9.22	9.33
Revenue Growth (YoY)	72.11%	13.98%	3.64%	-1.09%	37.41%
Cost of Revenue	559.16	303.59	190.97	150.4	101.18
Gross Profit	-540.4	-292.7	-181.41	-141.18	-91.86
Selling, General & Admin	205.54	86.24	54.19	37.73	26.2
Operating Expenses	205.54	86.24	54.19	37.73	26.2
Operating Income	-745.94	-378.94	-235.6	-178.91	-118.05
Interest & Investment Income	63.26	56.88	23.97	4.98	0.1
Other Non Operating Income (Expenses)	-1.94	-0.25	-0.59	-0.06	-0.06
Pretax Income	-684.63	-322.3	-212.22	-174	-118.01
Net Income	-684.63	-322.3	-212.22	-174	-118.01
Net Income to Common	-684.63	-322.3	-212.22	-174	-118.01
Shares Outstanding (Basic)	138	112	73	52	41
Shares Outstanding (Diluted)	138	112	73	52	41
Shares Change (YoY)	23.42%	52.83%	39.97%	25.91%	91.24%
EPS (Basic)	-4.97	-2.89	-2.91	-3.34	-2.85
EPS (Diluted)	-4.97	-2.89	-2.91	-3.34	-2.85
Free Cash Flow	-663.76	-307.94	-123.29	-139.09	-98.55
Free Cash Flow Per Share	-4.82	-2.76	-1.69	-2.67	-2.38
Operating Margin	-3977.30%	-3477.43%	-2464.41%	-1939.65%	-1265.83%
Profit Margin	-3650.39%	-2957.71%	-2219.87%	-1886.33%	-1265.38%
Free Cash Flow Margin	-3539.11%	-2825.88%	-1289.66%	-1507.92%	-1056.76%
EBITDA	-741.79	-376.16	-233.5	-177.53	-117.41
D&A For EBITDA	4.15	2.78	2.1	1.39	0.64
EBIT	-745.94	-378.94	-235.6	-178.91	-118.05

Source: S&P Global Market Intelligence. Standard template. Financial Sources.